Breast Cancer Trial, Recruiting NCT04065321 Sponsor: Shengjing Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT04065321
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your breast cancer tests positive for estrogen receptors and progesterone receptors (at least 10% each), but negative for a protein called HER2 (confirm with trial site)
  • Your cancer has a low growth rate, shown by a lab test called Ki-67 coming back at less than 20% (confirm with trial site)
  • Your cancer has not spread to your lymph nodes
  • You are receiving standard treatments such as chemotherapy, radiation, or hormone therapy as recommended by major cancer guidelines
  • You and your family have given written consent to take part in the trial

Who may not be able to join:

  • You have breast cancer in both breasts at the same time
  • You have a type of breast cancer called inflammatory breast cancer
  • You are currently pregnant or breastfeeding
  • You have a history of another type of cancer
  • You have previously had radiation therapy to your chest area

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jianyi Li, MD, Shengjing Hospital

Phone: +8618940257177

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shengjing Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2019
Est. completion
30 September 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov